Memantinhydrochlorid Beta

Memantine Hydrochloride, the active ingredient in Memantinhydrochlorid Beta, is an NMDA receptor antagonist presented as an oral formulation for oral use. It is employed in the symptomatic management of Alzheimer’s disease in adults, aiming to improve cognition and daily functioning. It is indicated for patients with mild to moderate disease and is administered under medical supervision.

GNH USA supplies Memantinhydrochlorid Beta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution.

Memantinhydrochlorid Beta is an NMDA receptor antagonist used in the treatment of Alzheimer’s disease and related cognitive decline. - Alzheimer's disease (moderate to severe): improves cognition, memory and daily functioning. - Alzheimer's disease (mild to moderate): may support cognitive performance and delay functional decline. - Alzheimer's disease (behavioral symptoms): may reduce agitation and aggression associated with the disease.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate pain in the head region. - Constipation: reduced bowel movements or hard stools. - Confusion: transient difficulty concentrating or thinking clearly. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: uncontrolled convulsive episodes. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Cardiac arrhythmia: irregular heart rhythm. - Hallucinations: visual or auditory disturbances. - Suicidal thoughts: emergence of depressive ideation or self‑harm urges.

Memantinhydrochlorid Beta should be used with caution in specific clinical situations. - Renal impairment: assess kidney function and consider dose adjustment. - History of seizures: monitor for increased seizure activity. - Cardiovascular disease: use cautiously in patients with unstable heart conditions. - Concomitant NMDA antagonists: avoid combined use to prevent additive toxicity. - Pregnancy: risk unknown; discuss potential benefits and risks with a healthcare professional. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantinhydrochlorid Beta may interact with other medicines; monitoring is advised. Major Interactions (Avoid): - Amantadine: combined NMDA antagonism can increase neurotoxicity. - Ketamine: additive CNS depression and severe dissociative effects. Moderate Interactions (Monitor Closely): - Anticholinergics: may diminish cognitive benefits of memantine. - Diuretics: can potentiate hypotensive effects. - CNS depressants (e.g., benzodiazepines): may enhance dizziness and sedation.